FDA reviewing higher dose Hyrimoz biosimilar
The US FDA has accepted a supplemental biologics license application (sBLA) from Sandoz for a high concentration formulation of 100 mg/mL (HCF) of its biosimilar, Hyrimoz.
Archives for July 21, 2022
US regRNA player gets $100m in Series B funding to treat genetic diseases at their core
US biotech, CAMP4 Therapeutics, has secured US$100m in a Series B financing round that it says will be used to accelerate expansion of its regulatory RNA (regRNA) platform.
Moderna and IVI sign MOU for vaccine R&D partnership
Moderna and the International Vaccine Institute (IVI) have signed a Memorandum of Understanding (MOU) to establish a partnership for vaccine research and development.
Yale, Vanderbilt, Morehouse join to increase trial diversity
The research institutions are joining on a community-based collaborative initiative to work toward greater study inclusion, supported by funding from PhRMA.
WuXi Biologics to build CRDMO center in Singapore
CDMO WuXi Biologics will invest $1.4bn in a 10 year investment plan to expand its research, development, and large-scale drug substance and drug product manufacturing capacity and capabilities in Singapore.